Home / NCIMI partners one step closer to large scale AI adopti…
NCIMI partners one step closer to large scale AI adoption
April 29, 2021
Caristo Diagnostics CaRi-Heart®
Working closely with the British Heart Foundation, Caristo has received CE-marking for its innovation: CaRi-Heart®️ cardiovascular risk prediction service.
It means patients in the UK and Europe can now benefit from personalised, accurate predictions of their risk of heart attack based on coronary inflammation.
The first-of-its-kind technology, CaRi-Heart® has the power to detect ‘invisible’ risk in people with possible heart disease by using routine heart scans already performed in clinical practice.
Optellum Virtual Nodule Clinic
Meanwhile, Optellum has received national press attention for its lung cancer diagnostic technology, Virtual Nodule Clinic.
Coverage on with inews and BBC South Today sets out what this could mean for the NHS and patients in the UK.
How Optellum is working to change the survival rates for lung cancer with an innovative AI platform
August 2, 2022
Optellum was founded with the vision of providing clinical decision support software that could help lung disease patients be diagnosed…
Optellum attains CE marking for Virtual Nodule Clinic
April 4, 2022
NCIMI events, speaking engagements, conferences and webinars
March 14, 2022
International Women’s Day | Meet Dr Laura Ismail
March 8, 2022